Ballarat Base Hospital, Drummond Street North, Ballarat, VIC 3350, Australia.
Med Oncol. 2011 Dec;28 Suppl 1:S395-7. doi: 10.1007/s12032-010-9719-5. Epub 2010 Nov 4.
We report the case of a 59-year-old man with advanced renal cell carcinoma who developed bilateral papilledema while on therapy with sunitinib, a multi-targeted tyrosine kinase inhibitor (TKI). While papilledema has been reported in association with another TKI (imatinib), the association between sunitinib and papilledema has not previously been reported in the literature.
我们报告了一例 59 岁男性病例，他在接受舒尼替尼（一种多靶点酪氨酸激酶抑制剂[TKI]）治疗期间出现双侧视乳头水肿。虽然已有报道称另一种 TKI（伊马替尼）与视乳头水肿有关，但舒尼替尼与视乳头水肿之间的关联以前尚未在文献中报道过。
